NICE recommends Eli Lilly’s psoriatic arthritis drug

pharmafile | August 9, 2018 | News story | Research and Development, Sales and Marketing Eli Lilly, England, NICE, Wales, psoriatic arthritis 

Eli Lilly have announced that the monoclonal antibody ixekizumab, has been recommended by NICE for use as a treatment option in England and Wales for adults with active psoriatic arthritis (PsA), after inadequate response to DMARDs (disease modifying antirheumatic drugs).

Ixekizumab was granted EU marketing authorisation in January 2018. The efficacy and safety of ixekizumab was determined from the findings of two randomized, double-blind, placebo-controlled Phase 3 studies involving 780 patients.

The NICE guidelines state that ixekizumab can be used alone or in combination with methotrexate for treating active psoriatic arthritis in adults.

“Up to 30 per cent of people with psoriasis will also develop psoriatic arthritis, a severe form of inflammatory arthritis that can cause swollen, stiff and painful joints.2  It can reduce physical function and lead to a reduction in quality of life2 so we are pleased that NICE is able to recommend this new treatment option,” said Dr. Arash Tahbaz, Senior Medical Director, Eli Lilly and Company, UK and Northern Europe.

Louis Goss

Related Content

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo

Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an …

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the …

Latest content